On Tuesday, Dr. Marty Makary announced his departure from the Food and Drug Administration (FDA), bringing an end to what has been described as a tumultuous tenure characterized by organizational upheaval and disagreements with the White House over drug approvals. According to multiple sources familiar with the matter, Makary's resignation comes amid reports of growing dissatisfaction from President Trump.
Kyle Diamantas, currently serving as the FDA’s deputy commissioner for food, will take on the role of acting commissioner pending a permanent replacement. This transition underscores the challenges facing the agency and its leadership in navigating complex regulatory issues during an intensely politicized era.
Makary's resignation follows several high-profile controversies that have rocked his 13-month term, including disputes over the approval process for certain products. These incidents have raised questions about the efficacy of FDA oversight under his leadership and could signal broader shifts within the agency’s structure.
The appointment of Diamantas as acting commissioner is seen by some experts as a pragmatic move to maintain continuity at a critical juncture in regulatory policy, despite mounting tensions with top administration officials. As the new interim leader, Diamantas will face the daunting task of balancing public health concerns with political pressures, a role that comes with significant responsibilities and potential challenges.
This development could have far-reaching implications for both domestic and international stakeholders involved in drug and medical device regulations. The search for a permanent successor to Makary is expected to be closely watched as it may shape future regulatory directions at the FDA.
This article was produced by AVALW News on Tuesday, May 12, 2026 based on reporting from 8 verified news sources. Our editorial process cross-references facts from multiple independent outlets to deliver accurate, comprehensive coverage. All original sources are linked below.